Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors

Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors

Latest milestone underscores accelerating regulatory momentum for the company’s lead investigational Helicon peptide, following FDA Fast Track Designation in desmoid tumorsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon TM peptide platform to drug historically undruggable targets, today announced that t…